ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

ImmunoGen reports successful 2022, eyes growth opportunities in 2023

ImmunoGen's strong 2022 performance, strategic partnerships, and positive market feedback set the stage for continued growth. While facing challenges in expenses and revenue targets, the company is well-positioned to capitalize on upcoming milestones and revenue streams.

ImmunoGen reports robust Q1 revenue, eyes growth opportunities

ImmunoGen's Q1 2023 earnings call showcased strong revenue performance
ELAHERE's market uptake and physician feedback remain positive
Operational challenges include increased expenses and regulatory evolution
Opportunities lie in resistance mechanisms study and program expansions

ImmunoGen reports strong Q2 revenue, focuses on Elahere growth

ImmunoGen's Q2 performance showed revenue growth and strong cash position
Elahere's success in trials and sales presents growth opportunities
Challenges include managing expenses and competition in the market
Opportunities lie in R&D investments, market expansion, and guideline updates

ImmunoGen reports robust Q3 earnings, eyes global expansion opportunities

ImmunoGen's strong financial performance and ELAHERE's success highlight a promising quarter.
Challenges include late responses in data sets and understanding the FR alpha and CDH overlap.
Opportunities lie in providing future revenue guidance, expanding globally, and exploring new molecules.
Overall, ImmunoGen's focus on ELAHERE's growth and strategic initiatives position it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO

ImmunoGen has a PDUFA on November 28. The NDA is based on data from the Soraya trial.

ImmunoGen Before The PDUFA

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS

ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.

Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.

ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

ImmunoGen, Inc. (NASDAQ:IMGN ) Q2 2022 Results Conference Call July 29, 2022 8:00 AM ET Company Participants Anabel Chan - Head of Investor Relations Mark Enyedy - President, CEO Anna Berkenblit - CMO Kristen Harrington-Smith - Chief Commercial Officer Susan Altschuller - CFO Conference Call Participants John Newman - Canaccord Genuity Michael Schmidt - Guggenheim Partners Etzer Darout - BMO Capital Markets Boris Peaker - Cowen Andy Hsieh - William Blair Kelly Shi - Jefferies Swayampakula Ramakanth - H.C. Wainwright Jonathan Chang - SVB Securities Operator Good morning and welcome to ImmunoGen's Second Quarter 2022 Financial and Operating Results Conference Call.

ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2022 Results - Earnings Call Transcript

ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results

ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results

ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results

PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha set for November 28, 2022. Confirmatory MIRASOL study trial readout of mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha expected early 2023.

ImmunoGen: Possible Accelerated FDA Approval For Ovarian Cancer Treatment

ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.

ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.

ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review

ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review. ImmunoGen's BLA acceptance is for mirvetuximab soravtansine monotherapy in patients with folate.

What's Going On With ImmunoGen Shares Today?

Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer treatment. The mirvetuximab soravtansine monotherapy has a Prescription Drug User Fee Act action date of Nov. 28.

ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US FDA with Priority Review

ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

ImmunoGen is a promising turnaround equity that is approaching its inflection point in growth. Mirvetuximab is poised to gain approval toward yearend.

ImmunoGen: An Inflection Point In Growth

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference

ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.

ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates

ImmunoGen, Inc. (NASDAQ:IMGN ) Q1 2022 Results Conference Call May 6, 2022 8:00 AM ET Company Participants Courtney O'Konek - Senior Director, Corporate Communications Mark Enyedy - President, CEO Anna Berkenblit - CMO Kristen Harrington-Smith - Chief Commercial Officer Susan Altschuller - CFO Conference Call Participants Boris Peaker - Cowen Kelly Shi - Jefferies Etzer Darout - BMO Capital Markets Jessica Fye - JPMorgan John Newman - Canaccord Joe Catanzaro - Piper Sandler Michael Schmidt - Guggenheim Andy Hsieh - William Blair Jonathan Chang - SVB Securities Operator Good morning and welcome to ImmunoGen's First Quarter 2022 Financial and Operating Results Conference Call. Today's conference is being recorded.

News for ImmunoGen Stock (IMGN)